氨苄西林/舒巴坦联合头孢他啶/阿维巴坦抗金属β-内酰胺酶CRAB的基因组学机制模型
本研究针对携带blaOXA-23、blaNDM-1或两者兼有的三株碳青霉烯耐药鲍曼不动杆菌(CRAB),采用静态浓度时间杀菌试验和机制性药效学模型(MBM)评估氨苄西林/舒巴坦联合头孢他啶/阿维巴坦的活性。联合用药显著降低细菌负荷,对AMA133的log10-CFU-时间曲线下面积约减少90%,对AMA3和AMA205约减少50-70%。模型预测与体外动态感染模型验证提示,blaNDM-1菌株需高剂量联合方案才能达到4-6 log10-CFU下降。
要点
- 联合方案对携带blaOXA-23和/或blaNDM-1的CRAB均有显著杀菌活性
- 阿维巴坦可增强舒巴坦活性,耐药层级为AMA3>AMA205>AMA133
- blaNDM-1菌株需高剂量氨苄西林/舒巴坦联合方案方能达到4-6 log10-CFU下降
核心结论
- 将基因组信息整合入机制性药效学模型可优化抗生素方案设计。
- 氨苄西林/舒巴坦联合头孢他啶/阿维巴坦对高度耐药CRAB显示有前景的活性,支持其临床应用于难治性感染。
研究设计与样本
- 针对AMA3、AMA133、AMA205三株CRAB进行基因型与表型耐药特征分析。
- 采用静态浓度时间杀菌(SCTK)试验评估抗菌活性,并基于SCTK数据构建纳入细菌耐药组的机制性药效学模型(MBM)。
- 用体外动态感染模型研究验证MBM预测。
主要发现
- 三株菌分别携带blaOXA-23(AMA133)、blaNDM-1(AMA3)或两者兼有(AMA205),均对氨苄西林/舒巴坦和头孢他啶/阿维巴坦耐药。
- 联合治疗显著降低细菌负荷:AMA133的log10-CFU-时间曲线下面积约减少90%,AMA3和AMA205约减少50-70%。
- MBM纳入NDM-1和OXA23对舒巴坦的水解及药物对青霉素结合蛋白的酰化动力学,EC50提示耐药层级为AMA3>AMA205>AMA133。
- 阿维巴坦显著增强舒巴坦活性;模拟与实验验证显示blaNDM-1菌株需高剂量联合方案达4-6 log10-CFU下降,AMA133较低剂量即可。
关键数值与推荐
- 联合方案对AMA133的log10-CFU-时间曲线下面积约减少90%。
- 联合方案对AMA3和AMA205的log10-CFU-时间曲线下面积约减少50-70%。
- blaNDM-1菌株需高剂量氨苄西林/舒巴坦联合方案以达到4-6 log10-CFU下降。
- EC50耐药层级:AMA3>AMA205>AMA133。
临床怎么用
- 对携带blaNDM-1的CRAB感染,考虑高剂量氨苄西林/舒巴坦联合头孢他啶/阿维巴坦方案。
- 对仅携带blaOXA-23的菌株,较低剂量联合方案可能足够,可结合基因型指导剂量选择。
- 基因组信息联合机制性药效学模型可用于个体化设计耐药CRAB的联合治疗方案。
局限性
- 研究仅纳入三株CRAB菌株,样本量有限。
- 结论主要基于体外静态杀菌试验和动态感染模型,尚缺乏临床数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections, driven by metallo- and class-D serine β-lactamases, pose significant therapeutic challenges. β-Lactam-based combinations offer a promising alternative to agents like colistin and tigecycline, which are associated with toxicity, and to cefiderocol, which is facing emerging resistance. METHODS: The pharmacodynamic activity of ampicillin/sulbactam and ceftazidime/avibactam was evaluated against three CRAB strains: AMA3, AMA133, and AMA205. Genotypic and phenotypic resistance profiles were characterized, and antibacterial activity was assessed using static concentration time-kill (SCTK) assays. A mechanism-based pharmacodynamic model (MBM) was developed using SCTK data, incorporating the bacterial resistome. This model informed the design of in vitro dynamic infection model studies, which were subsequently used to validate MBM predictions. RESULTS: These strains harboring resistance genes including blaOXA-23 (AMA133), blaNDM-1 (AMA3), or both (AMA205) were resistant to ampicillin/sulbactam and ceftazidime/avibactam. However, combination therapy significantly reduced bacterial burden, achieving approximately 90% reduction in the area under the log10-CFU-versus-time curve for AMA133, and approximately 50-70% for AMA3 and AMA205.The MBM incorporated sulbactam hydrolysis by NDM-1 and OXA23 enzymes, along with drug acylation kinetics to penicillin-binding proteins. Potency (EC50) estimates revealed a resistance hierarchy: AMA3 > AMA205 > AMA133. Avibactam notably enhanced sulbactam's activity. Simulations and experimental validation demonstrated that high-dose ampicillin/sulbactam combinations were required to achieve 4-6 log10-CFU reductions in blaNDM-1 strains, while lower doses sufficed for AMA133. CONCLUSIONS: This study highlights the potential of integrating genomic insights into MBM to optimize antibiotic regimens. The ampicillin/sulbactam and ceftazidime/avibactam combinations demonstrated promising activity against highly resistant CRAB strains, supporting their potential for clinical application in managing difficult-to-treat infections.
引用
- Arun B, Liu E, Vallé Q, et al. Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model. J Infect Dis. 2026. PMID: 41223187. doi:10.1093/infdis/jiaf567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。